SCYNEXIS, Inc. (SCYX)

Latest Financial Results

Q3 2022

Quarter Ended Sep 30, 2022

Earnings Release

HTML PDF

Earnings Webcast

Audio

10-Q

HTML PDF

XBRL

ZIP

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Latest Presentation

January 9, 2023

Investor Presentation

View Presentation View All

Latest News

View All News

December 1, 2022 • 8:00 AM

SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

November 30, 2022 • 8:30 AM

SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi

November 17, 2022 • 8:30 AM

SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

View All News

Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

View Leadership View Board of Directors

IR Contacts

Company

SCYNEXIS, Inc.
1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302
T: (201) 884-5485
info@scynexis.com

Investor Relations

Debbie Etchison
Executive Director, Communications and Investor Relations
debbie.etchison@scynexis.com

Media